Literature DB >> 8149699

Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus.

C A Abbott1, M I Mackness, S Kumar, A O Olukoga, C Gordon, S Arrol, D Bhatnagar, A J Boulton, P N Durrington.   

Abstract

1. The activity of serum butyrylcholinesterase ('pseudocholinesterase', EC3.1.1.8) was investigated in 56 patients with type 1 diabetes mellitus, 51 patients with type 2 diabetes mellitus and 101 healthy control subjects. 2. Butyrylcholinesterase activity was significantly elevated in both type 1 (8.10 +/- 3.35 units/ml) and type 2 (7.22 +/- 1.95 units/ml) diabetes compared with the control subjects (4.23 +/- 1.89 units/ml) (P < 0.001). 3. In the patients with type 1 and type 2 diabetes, serum butyrylcholinesterase activity was correlated with log serum fasting triacylglycerol concentration (r = 0.41 and r = 0.43, respectively, P < 0.001). In the type 2 population serum butyrylcholinesterase activity was also correlated with insulin sensitivity (r = -0.51, P < 0.001). 4. Serum butyrylcholinesterase activity was unrelated to age, gender, serum gamma-glutamyltranspeptidase activity, body mass index, or treatment for diabetes in both the diabetic populations. 5. In 37 non-diabetic patients with butyrylcholinesterase deficiency serum triacylglycerol levels were in the normal range. 6. These results are consistent with the view that butyrylcholinesterase may have a role in the altered lipoprotein metabolism in hypertriglyceridaemia associated with insulin insensitivity or insulin deficiency in diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8149699     DOI: 10.1042/cs0850077

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  17 in total

1.  Nongradient blue native gel analysis of serum proteins and in-gel detection of serum esterase activities.

Authors:  Nopporn Thangthaeng; Nathalie Sumien; Michael J Forster; Ruchir A Shah; Liang-Jun Yan
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-12-31       Impact factor: 3.205

Review 2.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Gohar Mushtaq; Nigel H Greig; Jalaluddin A Khan; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

3.  Acetylcholinesterase deficiency contributes to neuromuscular junction dysfunction in type 1 diabetic neuropathy.

Authors:  Carmen C Garcia; Joseph G Potian; Kormakur Hognason; Baskaran Thyagarajan; Lester G Sultatos; Nizar Souayah; Vanessa H Routh; Joseph J McArdle
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-26       Impact factor: 4.310

4.  GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE and secondary associations with metabolic risk factors.

Authors:  Beben Benyamin; Rita P Middelberg; Penelope A Lind; Anne M Valle; Scott Gordon; Dale R Nyholt; Sarah E Medland; Anjali K Henders; Andrew C Heath; Pamela A F Madden; Peter M Visscher; Daniel T O'Connor; Grant W Montgomery; Nicholas G Martin; John B Whitfield
Journal:  Hum Mol Genet       Date:  2011-08-23       Impact factor: 6.150

5.  Butyrylcholinesterase Deficiency Promotes Adipose Tissue Growth and Hepatic Lipid Accumulation in Male Mice on High-Fat Diet.

Authors:  Vicky Ping Chen; Yang Gao; Liyi Geng; Michael B Stout; Michael D Jensen; Stephen Brimijoin
Journal:  Endocrinology       Date:  2016-06-14       Impact factor: 4.736

Review 6.  Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation.

Authors:  Mohammad A Kamal; Shubha Priyamvada; Arivarasu N Anbazhagan; Nasimudeen R Jabir; Shams Tabrez; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2014-03       Impact factor: 4.388

7.  Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.

Authors:  Mohammad A Kamal; Shazi Shakil; Muhammad S Nawaz; Qian-Sheng Yu; David Tweedie; Y Tan; Xianqin Qu; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2017       Impact factor: 4.388

8.  The Correlative Study of Serum Pseudo-cholinesterase, Biological Parameters and Symptoms Among Occupational Workers.

Authors:  Tanasorn Tunsaringkarn; Kalaya Zapuang; Anusorn Rungsiyothin
Journal:  Indian J Clin Biochem       Date:  2013-04-03

9.  Butyrylcholinesterase K variant and the APOE-epsilon 4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients.

Authors:  Asad Vaisi-Raygani; Zohreh Rahimi; Haidar Tavilani; Tayebeh Pourmotabbed
Journal:  Mol Biol Rep       Date:  2009-08-15       Impact factor: 2.316

10.  Butyrylcholinesterase and γ-glutamyltransferase activities and oxidative stress markers are altered in metabolic syndrome, but are not affected by body mass index.

Authors:  Karine S De Bona; Gabriela Bonfanti; Paula E R Bitencourt; Lariane O Cargnelutti; Priscila S da Silva; Leidiane De Lucca; Victor C Pimentel; Etiane Tatsch; Thissiane L Gonçalves; Melissa Premaor; Rafael N Moresco; Maria Beatriz Moretto
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.